JPS60222472A - 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物 - Google Patents

新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物

Info

Publication number
JPS60222472A
JPS60222472A JP59064464A JP6446484A JPS60222472A JP S60222472 A JPS60222472 A JP S60222472A JP 59064464 A JP59064464 A JP 59064464A JP 6446484 A JP6446484 A JP 6446484A JP S60222472 A JPS60222472 A JP S60222472A
Authority
JP
Japan
Prior art keywords
compound
formula
acid addition
pharmaceutically acceptable
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59064464A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0313232B2 (OSRAM
Inventor
Hiroshi Otaka
博 大高
Toshiro Kanazawa
稔郎 金沢
Keizo Ito
敬三 伊藤
Goro Tsukamoto
悟郎 塚本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP59064464A priority Critical patent/JPS60222472A/ja
Priority to US06/715,813 priority patent/US4663325A/en
Priority to FI851217A priority patent/FI79101C/fi
Priority to CA000477468A priority patent/CA1248110A/en
Priority to DE8585103707T priority patent/DE3561199D1/de
Priority to EP85103707A priority patent/EP0159566B1/en
Priority to AT85103707T priority patent/ATE31411T1/de
Priority to GR850787A priority patent/GR850787B/el
Priority to NO851298A priority patent/NO163185C/no
Priority to ES541728A priority patent/ES8702393A1/es
Publication of JPS60222472A publication Critical patent/JPS60222472A/ja
Priority to ES556980A priority patent/ES8801236A1/es
Priority to ES556981A priority patent/ES8801237A1/es
Publication of JPH0313232B2 publication Critical patent/JPH0313232B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP59064464A 1984-03-30 1984-03-30 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物 Granted JPS60222472A (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP59064464A JPS60222472A (ja) 1984-03-30 1984-03-30 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
US06/715,813 US4663325A (en) 1984-03-30 1985-03-25 1-(2,3,4-tri-methoxybenzyl)-4[bis(4-fluorophenyl)methyl] piperazines are useful for treating cerebrovascular disease
FI851217A FI79101C (fi) 1984-03-30 1985-03-26 Foerfarande foer framstaellning av ett nytt terapeutiskt anvaendbart 1-(2,3,4-trimetoxibensyl)-4-/bis(4- fluorfenyl)metyl/piperazin.
CA000477468A CA1248110A (en) 1984-03-30 1985-03-26 Piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient
DE8585103707T DE3561199D1 (en) 1984-03-30 1985-03-27 Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient
EP85103707A EP0159566B1 (en) 1984-03-30 1985-03-27 Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient
AT85103707T ATE31411T1 (de) 1984-03-30 1985-03-27 Piperazin-derivate, verfahren zu ihrer herstellung und diese als aktive bestandteile enthaltende pharmazeutische zusammensetzungen.
GR850787A GR850787B (OSRAM) 1984-03-30 1985-03-28
NO851298A NO163185C (no) 1984-03-30 1985-03-29 Analogifremgangsmaate for fremstilling av nye terapeutisk aktive piperazinderivater.
ES541728A ES8702393A1 (es) 1984-03-30 1985-03-29 Un procedimiento para preparar un derivado de 1-bencil-4- benzhidril-piperazina
ES556980A ES8801236A1 (es) 1984-03-30 1986-07-29 Un procedimiento para preparar un derivado de 1-bencil-4-benzhidrilpiperazina
ES556981A ES8801237A1 (es) 1984-03-30 1986-07-29 Un procedimiento para preparar un derivado de 1-bencil-4-benzhidrilpiperazina

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59064464A JPS60222472A (ja) 1984-03-30 1984-03-30 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物

Publications (2)

Publication Number Publication Date
JPS60222472A true JPS60222472A (ja) 1985-11-07
JPH0313232B2 JPH0313232B2 (OSRAM) 1991-02-22

Family

ID=13258978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59064464A Granted JPS60222472A (ja) 1984-03-30 1984-03-30 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物

Country Status (10)

Country Link
US (1) US4663325A (OSRAM)
EP (1) EP0159566B1 (OSRAM)
JP (1) JPS60222472A (OSRAM)
AT (1) ATE31411T1 (OSRAM)
CA (1) CA1248110A (OSRAM)
DE (1) DE3561199D1 (OSRAM)
ES (3) ES8702393A1 (OSRAM)
FI (1) FI79101C (OSRAM)
GR (1) GR850787B (OSRAM)
NO (1) NO163185C (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038515A1 (en) * 1998-01-29 1999-08-05 Akzo Nobel N.V. Optic papillary circulation improving agents
WO2008105442A1 (ja) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド誘導体

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61161272A (ja) * 1985-01-11 1986-07-21 Kanebo Ltd 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
US4792553A (en) * 1986-02-04 1988-12-20 Terumo Kabushiki Kaisha Diene derivatives and vasodilators containing the same
FR2614021B1 (fr) * 1987-04-14 1991-03-01 Andre Buzas Derives de la 1-((1,1-diphenyl)-1-alcenyl)-piperazine, procede d'obtention et compositions pharmaceutiques les contenant
DE4108527A1 (de) * 1991-03-15 1992-09-17 Basf Ag Neue 1-(4-cyano-4-aryl-cyclohexyl)piperazine, ihre herstellung und verwendung
AU646926B2 (en) * 1991-03-20 1994-03-10 Duphar International Research B.V. Alkylenedioxyphenyl ether derivatives having anti-ischaemic, memory enhancing and anti-convulsive activity
BR9406080A (pt) * 1993-12-08 1996-02-06 Alcon Lab Inc Compostos que tem tanto antividade de anaonista potente de calcio como de antioxidante e uso dos mesmos como agentes citoprotetores
RU2204556C2 (ru) * 2001-06-18 2003-05-20 Федеральное государственное унитарное предприятие "Новокузнецкий научно-исследовательский химико-фармацевтический институт" Способ получения 1-(парахлорбензгидрил)-4-(2-оксиэтил)пиперазина
RS20050106A (sr) 2002-08-19 2007-11-15 Pfizer Products Inc., Kombinovana terapija hiperproliferativnih bolesti
US7433519B2 (en) 2003-04-04 2008-10-07 Avid Technology, Inc. Bitstream format for compressed image data
US7403561B2 (en) 2003-04-04 2008-07-22 Avid Technology, Inc. Fixed bit rate, intraframe compression and decompression of video
WO2004093813A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093816A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
BRPI0410840A (pt) * 2003-05-30 2006-07-04 Ranbaxy Lab Ltd derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
JP2008533044A (ja) * 2005-03-11 2008-08-21 ホン コン ナイトリック オキサイド リミテッド 内皮機能不全、アンギナおよび糖尿病のための組合せ治療
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
ATE551059T1 (de) * 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US8883844B2 (en) 2010-09-24 2014-11-11 Nitrogenix Inc. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
CN102936233B (zh) * 2012-11-16 2016-01-20 葛长乐 一种1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧苯基)哌嗪二盐酸盐晶型
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN107636792B (zh) * 2015-10-20 2019-05-14 韩国标准科学研究院 易于位置调节的电子显微镜用电子枪及包括其的电子显微镜
CN109666008A (zh) * 2018-12-31 2019-04-23 辰欣药业股份有限公司 一种盐酸洛美利嗪的合成方法
DK3911648T3 (da) 2019-01-18 2025-01-13 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB705979A (en) * 1951-03-22 1954-03-24 Henri Morren 1.4-aralkyl piperazines and process for the preparation thereof
FR1312427A (fr) * 1961-04-12 1962-12-21 Science Union Et Compagnie Soc Nouveaux dérivés de la pipérazine et leurs préparations
FR1303080A (fr) * 1961-07-25 1962-09-07 Science Union Et Compagnie Soc Pipérazines disubstituées
NL7306771A (OSRAM) * 1972-06-02 1973-12-04
DE2900810A1 (de) * 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
GB8320701D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038515A1 (en) * 1998-01-29 1999-08-05 Akzo Nobel N.V. Optic papillary circulation improving agents
WO2008105442A1 (ja) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド誘導体

Also Published As

Publication number Publication date
ATE31411T1 (de) 1988-01-15
FI79101C (fi) 1989-11-10
JPH0313232B2 (OSRAM) 1991-02-22
NO851298L (no) 1985-10-01
EP0159566A1 (en) 1985-10-30
ES8801237A1 (es) 1988-01-01
FI79101B (fi) 1989-07-31
GR850787B (OSRAM) 1985-11-25
ES8801236A1 (es) 1988-01-01
ES556981A0 (es) 1988-01-01
ES556980A0 (es) 1988-01-01
CA1248110A (en) 1989-01-03
FI851217A0 (fi) 1985-03-26
DE3561199D1 (en) 1988-01-28
ES8702393A1 (es) 1987-01-01
FI851217L (fi) 1985-10-01
EP0159566B1 (en) 1987-12-16
ES541728A0 (es) 1987-01-01
NO163185C (no) 1990-04-18
US4663325A (en) 1987-05-05

Similar Documents

Publication Publication Date Title
JPS60222472A (ja) 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
DE69123286T2 (de) Verwendung von 5-HT1A Rezeptoragonisten zur Hemmung der Magensäuresekretion
JPH08504798A (ja) 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
PL113208B1 (en) Process for preparing novel phthalazine derivatives
JPS6136282A (ja) 窒素を含む複素環式化合物からなる医薬品とその製造方法
EP0047536A2 (en) Substituted propylamines
US3091568A (en) Therapeutic phthalimidines for relieving cough and producing anesthesia
JPS6028979A (ja) イミダゾキナゾリン類化合物
JPH0687798A (ja) 新規なフェニルプロピニルアミン誘導体の製造法
US3580949A (en) N,n'-bis-(aminoalkyl)-benzyl-amines
JPS63501152A (ja) シス−ｎ−（２−アミノシクロ脂肪族）ベンゼンアセトアミドおよびベンズアミド鎮痙剤
US3948898A (en) 1,3-Dioxo-2-aminoalkyl-4,4-dimethyl-isoquinolines and salts thereof
JPH021439A (ja) ジアミン化合物、その製法及び該化合物を含有する高血圧症及び炎症を治療するための医薬
JPH0723365B2 (ja) フエノキシアルキルまたはチオフエノキシアルキル側鎖を有する新規ピペラジンカルボキシアミド化合物
JPS62181246A (ja) 生体活性ポリペプチド類に対し拮抗活性を有するグルタミン酸類およびアスパラギン酸類の新規酸素化アルキル誘導体およびその製造法
IE46547B1 (en) Amides
JPS59141558A (ja) ２−イミノ−ピロリジン類，その製造法および治療用組成物
TWI229671B (en) Substituted 3-pyridy1-4-arylpyrroles, and related therapeutic and prophylactic methods
US3579523A (en) Anilides of quinuclidine-2- and quinuclidine-3-carboxylic acid
JPS59199679A (ja) 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物
JPS60158190A (ja) ヒダントイン誘導体およびその製法ならびにそれを含有する医薬
JPS62123164A (ja) 新規なアミノアルキル置換尿素誘導体、その酸付加塩および鏡像異性体、それらの製法並びに薬用配合物
US4567181A (en) Bicyclo (4.2.0) 1,3,5-octatriene compounds and use as α-adrenergics
JPH03169841A (ja) アミノプロパノール誘導体およびそれを含有する薬剤組成物、ならびにそれらの製造方法
JPS6011898B2 (ja) 新ベンゼンスルホンアミド誘導体、それらの製造法およびそれらを含有する医薬組成物

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090222

Year of fee payment: 18

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090222

Year of fee payment: 18

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100222

Year of fee payment: 19

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100222

Year of fee payment: 19